Vicuron Pharmaceuticals to Present at the 23rd Annual JP Morgan Healthcare Conference
05 January 2005 - 11:30PM
PR Newswire (US)
Vicuron Pharmaceuticals to Present at the 23rd Annual JP Morgan
Healthcare Conference KING OF PRUSSIA, Pa., Jan. 5
/PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (Nasdaq:
MICU; Nuovo Mercato) today announced that George F. Horner III,
President and Chief Executive Officer, will present at the 23rd
Annual JPMorgan Healthcare Conference at 11:00 a.m. Pacific
Standard Time (2:00 p.m. EST) on Tuesday, January 11, 2005 at the
Westin St. Francis Hotel in San Francisco, California. To access
the live audio broadcast or the subsequent archived recording log
on to http://www.vicuron.com/ and click on the investor relations
section. Please connect to the website several minutes prior to the
start of the webcast to ensure adequate time for any software
download that may be necessary. The live broadcast will be archived
for 30 days. About Vicuron Pharmaceuticals Vicuron Pharmaceuticals
is a biopharmaceutical company focused on discovering, developing,
manufacturing and commercializing vital medicine for seriously ill
patients. The company has two New Drug Applications pending with
the U.S. Food and Drug Administration for its lead products,
dalbavancin, a novel intravenous antibiotic for the treatment of
serious Gram-positive infections, and anidulafungin, a novel
antifungal agent. Vicuron's versatile research engine integrates
industry-leading expertise in functional genomics, natural products
discovery, mechanism-based drug design and combinatorial and
medicinal chemistry. These approaches are yielding promising novel
and next- generation compounds, many of which are in the later
stages of preclinical development. In addition, the company has
research and development collaborations with leading pharmaceutical
companies, such as Novartis and Pfizer. Forward-Looking Statements
The presentation contains forward-looking statements that predict
or describe future events or trends. The matters described in these
forward-looking statements are subject to known and unknown risks,
uncertainties and other unpredictable factors, many of which are
beyond Vicuron's control. Vicuron faces many risks that could cause
its actual performance to differ materially from the results
predicted by its forward- looking statements, including the
possibilities that clinical trials and the results thereof might be
delayed or unsuccessful, that the timing of the filing of any new
drug application or any amendment to a new drug application might
be delayed, that clinical trials might indicate that a product
candidate is unsafe or ineffective, that the FDA might require
additional information to be submitted and additional actions to be
taken before it will make any decision, that any filed new drug
application may not be approved by the FDA, that ongoing
proprietary and collaborative research might not occur or yield
useful results, that the pipeline may not yield a new clinical
candidate or a commercial product, that a third party may not be
willing to license Vicuron's product candidates on terms acceptable
to it or at all, that competitors might develop superior
substitutes for Vicuron's products or market these competitive
products more effectively, that a sales force may not be developed
as contemplated and that one or more of Vicuron's product
candidates may not be commercialized successfully. The reports that
Vicuron files with the U.S. Securities and Exchange Commission
contain a fuller description of these and many other risks to which
Vicuron is subject. Because of those risks, Vicuron's actual
results, performance or achievements may differ materially from the
results, performance or achievements contemplated by its forward-
looking statement. The information set forth in the presentation
represents management's current expectations and intentions.
Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in the presentation. DATASOURCE:
Vicuron Pharmaceuticals Inc. CONTACT: Hala Mirza of WeissComm
Partners, +1-212-204-2080, or , or Aline Schimmel of Burns
McClellan Inc., +1-212- 213-0006; or , both for Vicuron
Pharmaceuticals Inc.; or Dov A. Goldstein, M.D. of Vicuron
Pharmaceuticals Inc., +1-610-205-2312, or Web site:
http://www.vicuron.com/
Copyright